Tecentriq atezolizumab: Additional Phase II data

Data from a cohort 1 of the open-label, international Phase II IMvigor210 trial in 119 evaluable patients with locally advanced or metastatic urothelial carcinoma in

Read the full 258 word article

User Sign In